<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750891</url>
  </required_header>
  <id_info>
    <org_study_id>DB601001</org_study_id>
    <secondary_id>JapicCTI-163216</secondary_id>
    <nct_id>NCT02750891</nct_id>
  </id_info>
  <brief_title>A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas</brief_title>
  <official_title>A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a phase 1/2, uncontrolled, open-label, multicenter study in patients with recurrent&#xD;
      and relapsed diffuse intrinsic pontine glioma, glioblastoma, or grade III or IV glioma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT (dose-limiting toxicity)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety and tolerability assessed by dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival （OS）</measure>
    <time_frame>24 months</time_frame>
    <description>Participants follow-up for overall survival will occur. Maximum follow-up time is 2 year after the initial administration of the last subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate（ORR）</measure>
    <time_frame>6 months</time_frame>
    <description>Antitumor effect as assessed according to the Response Assessment in Neuro-Oncology (RANO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability assessed by adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse events (SAEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability assessed by serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTH （delayed-type hypersensitivity）</measure>
    <time_frame>6 months</time_frame>
    <description>Explore efficacy related biomarkers assessed by delayed-type hypersensitivity (DTH) reactions to WT1 peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WT1 peptide-specific CTL-induction activity</measure>
    <time_frame>6 months</time_frame>
    <description>Explore efficacy related biomarkers assessed by WT1 peptide-specific CTL-induction activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of WT1 in biopsy tissues</measure>
    <time_frame>6 months</time_frame>
    <description>Explore efficacy related biomarkers assessed in biopsy tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of HLA in biopsy tissues</measure>
    <time_frame>6 months</time_frame>
    <description>Explore efficacy related biomarkers assessed in biopsy tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression of PD-L1 in biopsy tissues</measure>
    <time_frame>6 months</time_frame>
    <description>Explore efficacy related biomarkers assessed in biopsy tissues</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <arm_group>
    <arm_group_label>DSP-7888</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-7888</intervention_name>
    <description>Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks</description>
    <arm_group_label>DSP-7888</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients meeting any of the conditions a) to c) below:&#xD;
&#xD;
               1. Have a diagnosis of diffuse intrinsic pontine glioma on the basis of imaging&#xD;
                  findings on magnetic resonance imaging (MRI) and clinical course&#xD;
&#xD;
               2. Have histologically or cytologically confirmed glioblastoma&#xD;
&#xD;
               3. Not meeting a) and b) above, but have histologically or cytologically confirmed&#xD;
                  grade III or IV glioma&#xD;
&#xD;
          2. Patients who will be able to be hospitalized from the initial dose of DSP-7888 until&#xD;
             the end of the post-initial dose observation (In Phase 1 part only, patients may be&#xD;
             permitted to have a temporary overnight leave during the hospitalization.)&#xD;
&#xD;
          3. Patients aged &lt; 20 years at the time of informed consent&#xD;
&#xD;
          4. Patients for whom either the legally acceptable representative or the patient (if aged&#xD;
             ≥ 16 years) have provided written voluntary consent to participation in this study&#xD;
             after fully receiving and understanding the information about this study, including&#xD;
             study objectives, contents, expected pharmacological actions and effects, and&#xD;
             foreseeable risks&#xD;
&#xD;
          5. Patients for whom standard therapy failed or no standard therapy is established&#xD;
&#xD;
          6. Diffuse intrinsic pontine glioma patients must received radiotherapy-based treatment&#xD;
             or chemotherapy (if radiotherapy is not indicated) at least one cycle and subsequently&#xD;
             had tumor enlargement accompanied by tumor-related symptomatic worsening (except for&#xD;
             worsening due to dose reduction of steroid therapy for brain edema)&#xD;
&#xD;
          7. Glioblastoma patients and grade III or IV glioma patients must had radiologically&#xD;
             evident tumor re-enlargement or recurrence&#xD;
&#xD;
          8. Patients with an ECOG PS score of 0 to 2 at enrollment. Patients with a PS score of 3&#xD;
             or 4 due to neurological symptoms associated with the primary disease may be eligible&#xD;
             if appropriate in the opinion of the investigator or subinvestigator.&#xD;
&#xD;
          9. Patients with a life expectancy of 2 months (60 days)&#xD;
&#xD;
         10. Patients with a HLA type of HLA-A*24:02 or A*02:01/06&#xD;
&#xD;
         11. Patients with adequate major organ functions meeting the following criteria on the&#xD;
             basis of laboratory data within 28 days before enrollment:&#xD;
&#xD;
             Neutrophil count: 1000/μL Platelet count: 5.0 ×104/μL Hemoglobin: 9.0 g/dL Serum&#xD;
             creatinine: 2-fold the upper limit of the normal range of the study site (ULN) Total&#xD;
             bilirubin: 2-fold the ULN AST, ALT: 3-fold the ULN&#xD;
&#xD;
         12. Female patients of childbearing potential must have a negative pregnancy test within 4&#xD;
             weeks (28 days) before enrollment&#xD;
&#xD;
         13. Female patients of childbearing potential and male patients with female partners of&#xD;
             childbearing potential must agree to use appropriate contraception from the time of&#xD;
             consent until 180 days after the last dose of the study drug to avoid pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with grade 3 infection according to the CTCAE v4.0&#xD;
&#xD;
          2. Patients with a positive test result for HIV antibody, HBs antigen, or HCV antibody&#xD;
&#xD;
          3. Patients with multiple or disseminated primary lesions (Multiple nodules in the same&#xD;
             tumor cavity will be acceptable.)&#xD;
&#xD;
          4. Patients with other malignancies&#xD;
&#xD;
          5. Patients with significant diseases at enrollment that may affect study treatment, such&#xD;
             as New York Heart Association (NYHA) Functional Class III or IV heart disease, CTCAE&#xD;
             v4.0 grade 3 arrhythmia, angina pectoris, abnormal electrocardiogram findings,&#xD;
             interstitial pneumonia or pulmonary fibrosis&#xD;
&#xD;
          6. Patients with uncontrollable complications&#xD;
&#xD;
          7. Patients who underwent allogeneic hematopoietic stem cell transplant&#xD;
&#xD;
          8. Patients who received any of the following treatments within the specified period&#xD;
             before enrollment&#xD;
&#xD;
               -  Nitrosoureas, mitomycin C: &lt;42 days&#xD;
&#xD;
               -  Chemotherapy (including molecular-targeted drugs), radiotherapy: &lt;21 days&#xD;
&#xD;
               -  Surgery, blood transfusion, erythropoiesis-stimulating drugs, endocrine therapy,&#xD;
                  immunotherapy (including biological response modifier [BRM] therapy): &lt;14 days&#xD;
&#xD;
          9. Pregnant or breastfeeding women&#xD;
&#xD;
         10. Patients with concurrent autoimmune disease or a history of chronic or recurrent&#xD;
             autoimmune disease, or patients who require long-term systemic steroid therapy&#xD;
             (excluding therapy given on a PRN basis). However, steroid therapy for brain edema&#xD;
             (prednisolone-equivalent dose of 30 mg/m2) and steroid replacement therapy at a&#xD;
             physiologic dose will be acceptable.&#xD;
&#xD;
         11. Patients with any ongoing CTCAE v4.0 grade 2 adverse effects of prior treatment&#xD;
             (excluding alopecia and phlebitis)&#xD;
&#xD;
         12. Patients who received any other investigational product or post-marketing study drug&#xD;
             within 4 weeks (28 days) before enrollment&#xD;
&#xD;
         13. Patients with a history of allergy to any oil-based agents&#xD;
&#xD;
         14. Patients who previously received DSP-7888-containing WT1 peptide, or WT1 immunotherapy&#xD;
&#xD;
         15. Patients who are inappropriate for participation in the study for other reasons in the&#xD;
             opinion of the investigator or subinvestigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sumitomo Dainippon Pharma Co. Ltd. Japan</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>June 7, 2020</last_update_submitted>
  <last_update_submitted_qc>June 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high grade glioma</keyword>
  <keyword>HGG</keyword>
  <keyword>DIPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Diffuse Intrinsic Pontine Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

